Search

Your search keyword '"Kim, B.-G."' showing total 964 results

Search Constraints

Start Over You searched for: Author "Kim, B.-G." Remove constraint Author: "Kim, B.-G."
964 results on '"Kim, B.-G."'

Search Results

6. Dominant mobility modulation by the electric field effect at the LaAlO_3 / SrTiO_3 interface

7. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine : Subgroup Analysis of Participants From Asian Countries

8. Direct observation of oxygen superstructures in manganites

9. Atomic-scale images of charge ordering in a mixed-valence manganite

10. Optical Evidence of Multiphase Coexistence in Single Crystalline (La,Pr,Ca)MnO3

11. Magnetic relaxation in La0.250Pr0.375Ca0.375MnO3 with varying phase separation

12. Martensitic accommodation strain and the metal-insulator transition in manganites

13. Nanoscale anisotropic structural correlations in the paramagnetic and ferromagnetic phases of Nd0.5Sr0.5 MnO3

14. Multiphase segregation and metal-insulator transition in single crystal La(5/8-y)Pr(y)Ca(3/8)MnO3

21. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial

27. Optimal Supplemental Chromium Concentration for Alleviating Heat Stress in Broiler Chickens: A Meta-analysis.

32. 177O Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup

36. 101P Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia

37. 517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial

41. 732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E

45. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

46. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

47. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

48. Pyruvate dehydrogenase kinase 4 promotes ubiquitin-proteasome system-dependent muscle atrophy

49. Physics of Microyield of Magnesium Alloys with Titanium

Catalog

Books, media, physical & digital resources